Progen gets in synth
Wednesday, 02 July, 2008
Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.
The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.
It will also offer process development and manufacturing services to the biotechnology industry.
Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
